Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director | July 01, 2026 | July 02, 2026 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | September 29, 2022 | October 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2036-07-01 | Direct | 125,000 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 125,000 · Balance 125,000 F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
TherapeuticsMD, Inc.
Report date September 29, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,000 |
Reported balance
After 2022-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-29 · Grant · Acquired 5,000 · Balance 5,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 36,506 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001193125-26-294859 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2036-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 21:00 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 39,453 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001534002-26-000002 · form4-06182026_050614.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,453 Underlying: Ordinary Shares · 39,453 shares Expires 2036-06-16 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000950170-25-093468 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2035-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on the earlier of July 1, 2026 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:45 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 42,833 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001415889-25-018218 · form4-06252025_050611.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,833 Underlying: Ordinary Shares · 42,833 shares Expires 2035-06-22 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015322 · ownership.xml · nonDerivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 36,506 | $3.65 | $133,246.90 |
DisclosureSEC source: 0000950170-25-015322 · ownership.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:37 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare option (right to buy) · Derivative | 75,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0001415889-24-022457 · form4-08282024_080826.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 75,000 shares Expires 2034-08-25 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of August 26, 2024. F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 21:00 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000950170-24-081606 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2034-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2025, subject to the reporting person's continuous service with the issuer. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:47 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 23,458 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001479290-24-000089 · wk-form4_1714740423.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2034-04-30 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 01, 2024 Filed May 3, 2024 08:47 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000089 · wk-form4_1714740423.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,506 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 21:46 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001493152-23-023348 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2033-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:14 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 5,915 | $0.00 Strike: $33.61 | $0.00 |
DisclosureSEC source: 0001479290-23-000060 · wf-form4_168332125216237.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,915 Underlying: Common Stock · 5,915 shares Expires 2033-05-02 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Russell's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 03, 2023 Filed May 5, 2023 17:14 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000060 · wf-form4_168332125216237.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,506 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Mr. Russell's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 22:43 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051961 · doc4.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 1,984 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046966 · doc4.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,984 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on July 1, 2022. F3 · derivative.expiration_date: The RSUs vested on July 1, 2022. F1 · derivative.underlying_shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 1,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046966 · doc4.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:16 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001493152-22-018685 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer. Read SEC document |
| May 04, 2022 Filed May 6, 2022 18:18 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 11,343 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000059 · wf-form4_165187546396953.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,343 Underlying: Common Stock · 11,343 shares Expires 2032-05-03 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 04, 2022 Filed May 6, 2022 18:18 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-22-000059 · wf-form4_165187546396953.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,972 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 04, 2022 Filed May 13, 2022 18:17 UTC Amendment | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 10,756 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001479290-22-000071 · wf-form4a_165248019122400.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,756 Underlying: Common Stock · 10,756 shares Expires 2032-05-03 F1 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Russell's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:17 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | PurchaseCommon Stock | 6,400 | $15.74 | $100,741.12 |
DisclosureSEC source: 0001479290-21-000173 · wf-form4_163961742195547.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,913 F1 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.65 to $15.81. Mr. Russell undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-008440 · ownership.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on June 18, 2021. F3 · derivative.expiration_date: The RSUs vested on June 18, 2021. F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · derivative.underlying_shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 96,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-008440 · ownership.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:24 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001493152-21-015886 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: Will vest and become exercisable on July 1, 2022, subject to the reporting person's continuous service with the issuer. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:07 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 99,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007133 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,174 Underlying: Common Stock · 99,174 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 22:58 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionStock Option (right to buy) · Derivative | 24,720 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001493152-21-015786 · ownership.xml · derivative · entry 3 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 24,720 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 22:58 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | SaleCommon Shares, no par value | 4,720 | $2.97 | $14,018.40 |
DisclosureSEC source: 0001493152-21-015786 · ownership.xml · nonDerivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 22:58 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 24,720 | $2.20 | $54,384.00 |
DisclosureSEC source: 0001493152-21-015786 · ownership.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:12 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 7,551 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0001479290-21-000114 · wf-form4_162042912990502.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2031-05-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:12 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 4,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-21-000114 · wf-form4_162042912990502.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,513 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:12 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 51,789 | $0.13 | $6,665.24 |
DisclosureSEC source: 0000950138-20-000467 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.125 to $0.131, inclusive. Mr. Russell will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 21:01 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001493152-20-012533 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2030-07-01 F1 · derivative.exercise_date: Will become exercisable on July 1, 2021, based upon continued service on the board of directors. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 21:10 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-005820 · ownership.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,864 Underlying: Common Stock · 96,864 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 12,000 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001479290-20-000065 · wf-form4_158958207301515.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-05-13 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-20-000065 · wf-form4_158958207301515.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:48 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 12,042 | $2.96 | $35,644.32 |
DisclosureSEC source: 0000950138-20-000265 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,789 Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 21:14 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 10,000 | $2.77 | $27,700.00 |
DisclosureSEC source: 0001387131-19-006399 · ownership.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.75 to $2.78, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 10,000 | $2.99 | $29,900.00 |
DisclosureSEC source: 0001387131-19-006191 · ownership.xml · nonDerivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.00, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (2) to this Form 4. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 20:33 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 25,000 | $2.76 | $69,000.00 |
DisclosureSEC source: 0001387131-19-006191 · ownership.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.73 to $2.77, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in Footnote (1) to this Form 4. Read SEC document |
| July 01, 2019 Filed Jul 4, 2019 01:09 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001209191-19-041304 · doc4.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2020, based upon continued service on the board of directors. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 23:03 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001387131-19-004588 · russell-form4_062019.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-20 Read SEC document |
| May 15, 2019 Filed May 17, 2019 11:08 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 26,759 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000314 · edgar.xml · nonDerivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,831 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| May 15, 2019 Filed May 17, 2019 11:08 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 11,764 | $15.21 | $178,930.44 |
DisclosureSEC source: 0000950138-19-000314 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,072 Read SEC document |
| May 09, 2019 Filed May 10, 2019 21:09 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 9,000 | $0.00 Strike: $12.82 | $0.00 |
DisclosureSEC source: 0001479290-19-000060 · wf-form4_155753693463342.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 09, 2019 Filed May 10, 2019 21:09 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-19-000060 · wf-form4_155753693463342.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001387131-18-003030 · russell-form4_070218.xml · derivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-07-02 Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 22:34 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 40,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-18-041308 · doc4.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2023-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2019, based upon continued service on the board of directors. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:21 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 26,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000415 · edgar.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,836 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:30 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 6,000 | $0.00 Strike: $29.15 | $0.00 |
DisclosureSEC source: 0001479290-18-000080 · wf-form4_152608499215478.xml · derivative · entry 2 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-05-09 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:30 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-18-000080 · wf-form4_152608499215478.xml · nonDerivative · entry 1 Russell Angus C. · CIK 0001534002 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Russell's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.